31例鼻腔鼻窦神经内分泌癌临床分析  

Clinical analysis of 31 patients with sinonasal neuroendocrine carcinoma

作　　者：彭金林 李笑秋 刘柱 崔哲卿 金红军[1] PENG Jinlin;LI Xiaoqiu;LIU Zhu;CUI Zheqing;JIN Hongjun(Department of Rhinology,the First Affiliated Hospital of Zhengzhou University,Zhengzhou,450052,China;Department of Otolaryngology Head and Neck Surgery,Zhengzhou People's Hospital;Department of Otolaryngology Head and Neck Surgery,Zhengzhou Central Hospital)

机构地区：[1]郑州大学第一附属医院鼻科,郑州450052 [2]郑州人民医院耳鼻咽喉头颈外科 [3]郑州市中心医院耳鼻咽喉头颈外科

出　　处：《临床耳鼻咽喉头颈外科杂志》2022年第1期32-35,共4页Journal of Clinical Otorhinolaryngology Head And Neck Surgery

基　　金：河南省科技攻关计划(No:LHGJ20190186)。

摘　　要：目的:探讨鼻腔鼻窦神经内分泌癌(SNEC)的临床特点及影响预后的因素。方法:回顾性分析31例确诊为SNEC患者的临床资料。31例患者中,单纯手术切除3例,手术+放疗4例,手术+化疗4例,手术+放化疗10例,未行手术单纯放化疗10例。随访8~64个月。结果:至随访结束,2例患者失访,17例死亡,12例存活,8例复发,5年总生存率36.4%,高TNM分期、淋巴结转移、颅底浸润以及Ki-67≥55%是其预后不良因素。结论:SNEC是一种罕见的侵袭性肿瘤,预后差、局部复发率高、有转移倾向,且起病隐匿,手术联合放化疗的综合治疗仍是最佳的治疗方式。Objective: To investigate the characteristics and prognostic factors of sinonasal neuroendocrine carcinoma(SNEC). Methods: The clinical data of 31 patients with SNEC were retrospectively analyzed. Among the 31 patients, 3 cases were simply surgically removed, 4 cases were surgery + radiotherapy, 4 cases were surgery + chemotherapy, 10 cases were surgery + chemoradiotherapy, and 10 cases were simply given chemoradiotherapy without surgery. The study follow-up 8-64 months. Results: By the end of follow-up, 2 patients were lost to follow-up, 17 died, 12 survival, 8 relapsed and 5-year survival rate was 36.4%. High TNM stage, lymph node metastasis, skull base infiltration and Ki-67≥55% were the negative prognostic factors for survival. Conclusion: SNEC is a rare aggressive tumor, with poor prognosis, high local recurrence rate, metastasis tendency, hidden disease. The comprehensive treatment of surgery combined with chemoradiotherapy is still the best treatment.

关 键 词：神经内分泌癌 鼻肿瘤 预后 

分 类 号：R739.62[医药卫生—肿瘤]